Search results
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $7.00 Consensus PT from Analysts
ETF DAILY NEWS· 6 days agoTaysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) has received an average rating of “Buy” from the nine research firms that are currently covering the company, Marketbeat reports.
With Duchenne decision ahead, FDA’s Marks pushes for speedy gene therapy approvals
BioPharma Dive via Yahoo Finance· 1 day agoBut the head of the FDA’s CBER office didn’t tip where the agency stands on potentially broadening...
Gene Therapy for Cystic Fibrosis: What the Current Research Says
Healthline· 1 day agoWhile gene therapy for cystic fibrosis is still in the research phase, researchers aim to correct the defective gene responsible for the disease. Current ...
Evotec ends gene therapy business, shuts down facility in Austria
Endpoints News· 3 days agoEvotec has provided further updates to its “priority reset” as the CRDMO exits the gene therapy...
Local cell and gene therapy sector reeled in $7.6B in private investment capital in last five years...
The Business Journals· 2 days agoThe Philadelphia region is now home to more than 10% of the world’s cell and gene therapy companies....
12-Year-Old Begins Newly Approved Sickle Cell Gene Therapy That Could Provide Cure
Black Enterprise· 1 day agoKendric Cromer, 12, is the first patient in the United States to undergo a newly approved gene ...
Flexibility of alternative trial designs crucial for cell and gene therapy research
Clinical Trials Arena via Yahoo Finance· 5 days agoInnovative trial designs, like single group assignment, adaptive, basket, umbrella and platform...
Evotec makes 'strategic exit' from gene therapy as part of wider shake-up
FierceBiotech· 3 days agoA month after Evotec first alluded to a “strategic reset” to rebalance the company, the German biotech has revealed the end of its gene therapy aspirations ...
...California Institute for Regenerative Medicine (CIRM) Accelerating Medicines Partnership (AMP)...
WKBN 27 Youngstown· 2 days agoAndelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selected ...
Investing in Taysha Gene Therapies Inc
Knox Daily· 5 days agoIn a filing, Taysha Gene Therapies Inc revealed its 10% Owner Manning Paul B acquired Company’s shares for reported $0.16 million on Nov 17 ’23. In the deal valued at $1.63 per share,100,000 ...
